Universities undertake the vast majority of publicly funded research in Germany and therefore bear a duty to contribute to world health efforts. So far, involvement and affect of German medical faculties in world health are unknown. Our goal was to systematically asses and consider German medical faculties’ contribution to world health associated research and education, in addition to their insurance policies and practices regarding open entry publishing and equitable licensing.
We assessed the involvement in world health of all 36 publicly funded medical faculties in Germany throughout 2010-2014 in three areas: innovation, entry and education, utilizing the next indicators: research funding and publications centered on world health or poverty-related and uncared for illnesses; open entry publishing and insurance policies selling entry to medical improvements worldwide; provision of world health education. Data had been gathered from public databases, college web sites and questionnaires despatched to particular person universities for validation and triangulation.
There was a excessive degree of variability between establishments and indicators. The proportion of research funding for poverty-related and uncared for illnesses research ranged between 0.0-1.1%. The prime 5 establishments obtained practically 85% of the entire poverty-related and uncared for illnesses research funding. 20 of 36 universities had an institutional open entry publishing coverage, 19 had an open entry publishing fund, 16 had neither. Only one college reported having used an equitable licensing coverage.
22 of 36 faculties supplied some world health education, however solely certainly one of them included world health in their core undergraduate medical curriculum as a obligatory course with extra than simply single lectures.Obtained information point out that world health and poverty-related and uncared for illnesses research at German medical faculties is very concentrated in just a few establishments, open-access publishing and equitable licensing insurance policies are principally absent, and solely little world health education exists. Universities and authorities ought to deal with world health strategically in each research and education at medical faculties to mirror the nation’s financial and political weight and human useful resource potential.
Improving Graduate Medical Education Through Faculty Empowerment Instead of Detailed Guidelines.
Calls for enchancment and reform in graduate medical education (GME) have led to extra element in instructional and curricular tips. The present degree of element in curriculum tips for GME coaching packages is excessive, encompassing, for instance, competency frameworks, entrustable skilled actions, and milestones. In addition, school should make use of an rising variety of evaluation instruments and elaborate portfolio methods for his or her residents. It is questionable whether or not any additional improve in curriculum element and evaluation codecs results in higher GME packages.
Focusing on this sort of system improvement could even result in much less engaged school if school aren’t inspired to make use of their very own skilled judgement and creativity for instructing residents. Therefore, school members have to be empowered to have interaction curricular innovation, since system improvement alone won’t consequence in higher coaching packages. Raising school members’ consciousness of their virtues and worth as academics and involving them in the controversy about how GME may be enhanced may improve their engagement in resident coaching.
Using a Facebook group to facilitate school-student interactions throughout preclinical medical education: a retrospective survey evaluation.
<AbstractText>Strong learner-teacher relationships are related to extra profitable studying outcomes. With shortened modular curricula and elevated availability of on-line sources, fostering school interplay with preclinical medical college students has develop into more difficult. We sought to boost learner-teacher relationships by participating in dialogue with preclinical medical college students in their very own on-line area.
</AbstractText><AbstractText>We utilized a closed Facebook dialogue group, the place school and college students voluntarily joined in casual discussions and shared bulletins associated to their programs. The closed dialogue group allowed solely collaborating college students and school to see others’ posts inside the group. This supplied a platform to freely work together inside the confines of the group whereas sustaining privateness for the non-public Facebook accounts of each school and college students. We utilized the dialogue group via three separate organ system-based modules for 14 weeks.
Afterward, college students had been requested to finish an nameless, voluntary on-line survey about their expertise.</AbstractText><AbstractText>94.1% (160/170) of enrolled second-year medical college students joined the voluntary FB dialogue group. There had been 214 posts, 628 feedback, and 4166 reactions in this dialogue group in the course of the three modules. Of the scholars in the group, 74.4% (119/160) responded to the web survey. Overall, college students strongly agreed that the Facebook dialogue group fostered higher rapport with school, helped content material studying, and improved emotional well-being. Also, they felt extra comfy searching for tutorial assist after utilizing the dialogue group.
They reported a slight desire for Facebook over e mail as a medium for asking questions, however no desire for both as a medium for distributing bulletins. Students overwhelmingly advisable that the dialogue group must be continued in future years.</AbstractText><AbstractText>The Facebook dialogue group was a free, environment friendly, and efficient technique of cultivating the learner-teacher relationship with the preclinical medical college students, ensuing in reported enhancement of studying and morale.</AbstractText>
Effectiveness and Needs Assessment of Faculty Development Programme for Medical Education: Experience from Saudi Arabia.
Faculty members are crucial useful resource in any establishment of upper education as medical education has been, and continues to be, a precedence for medical faculties in Saudi Arabia. This research aimed to evaluate school members’ perceptions of college improvement programmes (FDPs) in supporting necessary targets in medical education. In addition, this research aimed to evaluate school members’ perceived wants.This cross-sectional research was carried out between August 2016 and August 2017 and concerned contributors from six universities in Saudi Arabia’s Western Province.
The survey consisted of 31 gadgets designed to evaluate FDP effectiveness and 49 gadgets designed to evaluate wants in FDPs.A complete of 210 school members participated in the research (response price = 52.5%) and recognized 49 wants. Faculty members perceived private enchancment in delivering medical education and the supply of larger instructional involvement as the simplest issues in an FDP. The respondents thought of 13 must be of utmost significance; the remaining had been thought of necessary.
Exosome Component 9 Protein |
|||
| abx262123-5mg | Abbexa | 5 mg | EUR 225 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| 20-abx318649 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody |
|||
| 20-abx312069 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody |
|||
| 20-abx301763 | Abbexa |
|
|
Exosome Component 5 (EXOSC5) Antibody |
|||
| 20-abx302857 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx034983-400ul | Abbexa | 400 ul | EUR 627.6 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx034983-80l | Abbexa | 80 µl | EUR 343.2 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx176346 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx172308 | Abbexa |
|
|
Exosome Component 7 (EXOSC7) Antibody |
|||
| 20-abx124556 | Abbexa |
|
|
Exosome Component 4 (EXOSC4) Antibody |
|||
| 20-abx124664 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody |
|||
| 20-abx125829 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx125830 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody |
|||
| 20-abx125831 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx232898-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx232901-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx232902-100ug | Abbexa | 100 ug | EUR 661.2 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx232903-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx232904-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx232905-100ug | Abbexa | 100 ug | EUR 610.8 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx232906-100ug | Abbexa | 100 ug | EUR 661.2 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx232907-100ug | Abbexa | 100 ug | EUR 577.2 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| 20-abx112409 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx112411 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody |
|||
| 20-abx112412 | Abbexa |
|
|
Exosome Component 4 (EXOSC4) Antibody |
|||
| 20-abx112413 | Abbexa |
|
|
Exosome Component 5 (EXOSC5) Antibody |
|||
| 20-abx112414 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody |
|||
| 20-abx112415 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody |
|||
| 20-abx003377 | Abbexa |
|
|
Exosome Component 2 (EXOSC2) Antibody |
|||
| 20-abx003412 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx030303-400ul | Abbexa | 400 ul | EUR 627.6 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx030303-80l | Abbexa | 80 µl | EUR 343.2 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx031706-400ul | Abbexa | 400 ul | EUR 627.6 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx031706-80l | Abbexa | 80 µl | EUR 343.2 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx029390-400ul | Abbexa | 400 ul | EUR 627.6 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx029390-80l | Abbexa | 80 µl | EUR 343.2 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx003377-100l | Abbexa | 100 µl | EUR 400 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx003377-20l | Abbexa | 20 µl | EUR 175 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx003377-50l | Abbexa | 50 µl | EUR 275 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx301763-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx301763-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx301763-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx302857-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx302857-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx302857-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx125829-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx125829-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx125829-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx125830-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx125830-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx125830-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx125831-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx125831-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx125831-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx112409-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx112411-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx112412-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx112413-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx112414-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx112415-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx034983-100g | Abbexa | 100 µg | EUR 281.25 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx176346-1096tests | Abbexa | 10 × 96 tests | EUR 750 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx176346-596tests | Abbexa | 5 × 96 tests | EUR 337.5 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx176346-96tests | Abbexa | 96 tests | EUR 275 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx232898-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx232901-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx232902-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx232903-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx232904-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 5 (EXOSC5) Antibody |
|||
| abx232905-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx232906-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx232907-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx029390-400l | Abbexa | 400 µl | EUR 518.75 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx312069-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx312069-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 3 (EXOSC3) Antibody |
|||
| abx312069-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody |
|||
| abx030303-400l | Abbexa | 400 µl | EUR 518.75 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx031706-400l | Abbexa | 400 µl | EUR 518.75 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx124556-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx124556-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 7 (EXOSC7) Antibody |
|||
| abx124556-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx124664-100l | Abbexa | 100 µl | EUR 175 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx124664-1ml | Abbexa | 1 ml | EUR 400 |
Exosome Component 4 (EXOSC4) Antibody |
|||
| abx124664-200l | Abbexa | 200 µl | EUR 275 |
Exosome Component 2 (EXOSC2) Antibody |
|||
| abx172308-1ml | Abbexa | 1 ml | EUR 787.5 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx318649-100l | Abbexa | 100 µl | EUR 250 |
Exosome Component 8 (EXOSC8) Antibody |
|||
| abx318649-50l | Abbexa | 50 µl | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| 20-abx334343 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx232899-100ug | Abbexa | 100 ug | EUR 661.2 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx232900-100ug | Abbexa | 100 ug | EUR 610.8 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| 20-abx112410 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx112410-100l | Abbexa | 100 µl | EUR 612.5 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx232899-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx232900-100g | Abbexa | 100 µg | EUR 350 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx334343-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx334343-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody |
|||
| abx334343-50g | Abbexa | 50 µg | EUR 250 |
Goat Anti Human Exosome Component 9 (C-Terminal) Polyclonal Antibody |
|||
| CPBT-67673GH | Creative Diagnostics | 0.1 mg | EUR 1008 |
Exosome Component 5 (EXOSC5) Antibody (HRP) |
|||
| 20-abx311411 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody (HRP) |
|||
| 20-abx312070 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody (HRP) |
|||
| 20-abx312486 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (HRP) |
|||
| 20-abx310194 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (HRP) |
|||
| abx310194-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 8 (EXOSC8) Antibody (HRP) |
|||
| abx310194-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 8 (EXOSC8) Antibody (HRP) |
|||
| abx310194-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (HRP) |
|||
| abx311411-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 5 (EXOSC5) Antibody (HRP) |
|||
| abx311411-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 5 (EXOSC5) Antibody (HRP) |
|||
| abx311411-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 3 (EXOSC3) Antibody (HRP) |
|||
| abx312070-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 3 (EXOSC3) Antibody (HRP) |
|||
| abx312070-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 3 (EXOSC3) Antibody (HRP) |
|||
| abx312070-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody (HRP) |
|||
| abx312486-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 1 (EXOSC1) Antibody (HRP) |
|||
| abx312486-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 1 (EXOSC1) Antibody (HRP) |
|||
| abx312486-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (FITC) |
|||
| 20-abx311412 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody (FITC) |
|||
| 20-abx312071 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody (FITC) |
|||
| 20-abx312487 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody (HRP) |
|||
| 20-abx335640 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (FITC) |
|||
| 20-abx310195 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (FITC) |
|||
| abx310195-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 8 (EXOSC8) Antibody (FITC) |
|||
| abx310195-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 8 (EXOSC8) Antibody (FITC) |
|||
| abx310195-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (FITC) |
|||
| abx311412-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 5 (EXOSC5) Antibody (FITC) |
|||
| abx311412-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 5 (EXOSC5) Antibody (FITC) |
|||
| abx311412-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 3 (EXOSC3) Antibody (FITC) |
|||
| abx312071-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 3 (EXOSC3) Antibody (FITC) |
|||
| abx312071-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 3 (EXOSC3) Antibody (FITC) |
|||
| abx312071-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody (FITC) |
|||
| abx312487-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 1 (EXOSC1) Antibody (FITC) |
|||
| abx312487-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 1 (EXOSC1) Antibody (FITC) |
|||
| abx312487-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 10 (EXOSC10) Antibody (HRP) |
|||
| abx335640-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 10 (EXOSC10) Antibody (HRP) |
|||
| abx335640-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody (HRP) |
|||
| abx335640-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 10 (EXOSC10) Antibody (FITC) |
|||
| 20-abx335641 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody (FITC) |
|||
| abx335641-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 10 (EXOSC10) Antibody (FITC) |
|||
| abx335641-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody (FITC) |
|||
| abx335641-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (Biotin) |
|||
| 20-abx311413 | Abbexa |
|
|
Exosome Component 3 (EXOSC3) Antibody (Biotin) |
|||
| 20-abx312072 | Abbexa |
|
|
Exosome Component 1 (EXOSC1) Antibody (Biotin) |
|||
| 20-abx312488 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (Biotin) |
|||
| 20-abx310196 | Abbexa |
|
|
Exosome Component 8 (EXOSC8) Antibody (Biotin) |
|||
| abx310196-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 8 (EXOSC8) Antibody (Biotin) |
|||
| abx310196-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 8 (EXOSC8) Antibody (Biotin) |
|||
| abx310196-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 5 (EXOSC5) Antibody (Biotin) |
|||
| abx311413-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 5 (EXOSC5) Antibody (Biotin) |
|||
| abx311413-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 5 (EXOSC5) Antibody (Biotin) |
|||
| abx311413-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 3 (EXOSC3) Antibody (Biotin) |
|||
| abx312072-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 3 (EXOSC3) Antibody (Biotin) |
|||
| abx312072-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 3 (EXOSC3) Antibody (Biotin) |
|||
| abx312072-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 1 (EXOSC1) Antibody (Biotin) |
|||
| abx312488-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 1 (EXOSC1) Antibody (Biotin) |
|||
| abx312488-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 1 (EXOSC1) Antibody (Biotin) |
|||
| abx312488-50g | Abbexa | 50 µg | EUR 250 |
Exosome Component 10 (EXOSC10) Antibody (Biotin) |
|||
| 20-abx335642 | Abbexa |
|
|
Exosome Component 10 (EXOSC10) Antibody (Biotin) |
|||
| abx335642-100g | Abbexa | 100 µg | EUR 362.5 |
Exosome Component 10 (EXOSC10) Antibody (Biotin) |
|||
| abx335642-20g | Abbexa | 20 µg | EUR 162.5 |
Exosome Component 10 (EXOSC10) Antibody (Biotin) |
|||
| abx335642-50g | Abbexa | 50 µg | EUR 250 |
Recombinant Human Exosome Component 9 |
|||
| 7-05902 | CHI Scientific | 2µg | Ask for price |
Recombinant Human Exosome Component 9 |
|||
| 7-05903 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Exosome Component 9 |
|||
| 7-05904 | CHI Scientific | 1mg | Ask for price |
Exosome Component 9 Human Recombinant |
|||
| rAP-3266 | Angio Proteomie | Inquiry | Ask for price |
Exosome Component 2 (EXOSC2) Polyclonal Antibody |
|||
| CAU30293-100ul | Biomatik Corporation | 100ul | EUR 235.2 |
Exosome Component 2 (EXOSC2) Polyclonal Antibody |
|||
| CAU30293-200ul | Biomatik Corporation | 200ul | EUR 294 |
Human anti exosome component 10(EXOSC10) antibody Elisa Kit |
|||
| EK714539 | AFG Bioscience LLC | 96 Wells | EUR 0.46 |
Polyclonal Antibody to Exosome Component 2 (EXOSC2) |
|||
| PAH822Hu01 | Cloud-Clone | 100ul | EUR 245 |
This research assessed and recognized school wants and necessary expertise to contemplate when establishing an FDP. Furthermore, it supplied info addressing the wants of, or gaps between, present and desired situations in medical education in Saudi Arabia. The research additionally recognized crucial components (i.e. private enchancment) of faculty-perceived effectiveness for a profitable FDP in medical education.